Your browser is no longer supported. Please, upgrade your browser.
ALLK [NASD]
Allakos Inc.
Index- P/E- EPS (ttm)-2.74 Insider Own1.20% Shs Outstand48.95M Perf Week-4.33%
Market Cap5.80B Forward P/E- EPS next Y-3.76 Insider Trans-21.51% Shs Float47.08M Perf Month-17.02%
Income-133.80M PEG- EPS next Q-0.86 Inst Own70.90% Short Float6.30% Perf Quarter7.52%
Sales- P/S- EPS this Y-87.00% Inst Trans7.70% Short Ratio9.40 Perf Half Y30.51%
Book/sh8.45 P/B13.39 EPS next Y-20.50% ROA-27.70% Target Price134.00 Perf Year70.44%
Cash/sh8.19 P/C13.81 EPS next 5Y-10.50% ROE-29.20% 52W Range41.60 - 157.98 Perf YTD-19.19%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-28.38% Beta-
Dividend %- Quick Ratio22.40 Sales past 5Y- Gross Margin- 52W Low171.94% ATR7.82
Employees114 Current Ratio22.40 Sales Q/Q- Oper. Margin- RSI (14)34.27 Volatility7.18% 5.83%
OptionableYes Debt/Eq0.00 EPS Q/Q-83.10% Profit Margin- Rel Volume0.92 Prev Close111.38
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume315.56K Price113.14
Recom2.10 SMA20-14.35% SMA50-14.91% SMA20016.24% Volume289,318 Change1.58%
Feb-24-21Initiated Cantor Fitzgerald Overweight $218
Jan-15-21Initiated BofA Securities Buy $145
Dec-21-20Initiated SVB Leerink Outperform $150
Feb-27-20Initiated Barclays Underweight $36
Feb-04-20Resumed Goldman Neutral $89 → $94
Aug-13-18Initiated William Blair Outperform
Aug-13-18Initiated Jefferies Buy $53
Aug-13-18Initiated Goldman Neutral $31
Mar-01-21 08:00AM  
Feb-17-21 02:22AM  
Jan-13-21 11:16PM  
Jan-06-21 11:16AM  
Dec-22-20 04:05PM  
Dec-21-20 10:07AM  
Dec-10-20 10:33PM  
Nov-09-20 08:01AM  
Nov-02-20 08:00AM  
Oct-28-20 08:20PM  
07:41AM  
Oct-27-20 07:56PM  
04:09PM  
Oct-26-20 07:00AM  
07:00AM  
Oct-21-20 05:00PM  
Aug-28-20 06:53AM  
Aug-10-20 08:00AM  
Jul-18-20 09:55AM  
Jul-05-20 03:31PM  
Jun-16-20 06:30PM  
Jun-03-20 08:01AM  
May-21-20 08:01AM  
May-15-20 09:02AM  
May-14-20 12:00PM  
May-11-20 12:40PM  
10:31AM  
10:03AM  
08:01AM  
08:00AM  
May-10-20 07:20PM  
05:10PM  
02:11PM  
01:45PM  
01:30PM  
May-09-20 02:43PM  
12:22PM  
12:00PM  
07:20AM  
May-08-20 04:00PM  
01:55PM  
01:30PM  
01:23PM  
12:00PM  
10:55AM  
09:38AM  
May-07-20 06:35PM  
02:15PM  
01:00PM  
11:12AM  
10:18AM  
09:27AM  
May-06-20 05:00PM  
04:50PM  
01:27PM  
10:12AM  
09:41AM  
May-05-20 05:10PM  
04:10PM  
09:17AM  
09:00AM  
May-04-20 03:45PM  
01:26PM  
09:29AM  
09:24AM  
08:01AM  
May-03-20 05:16PM  
02:25PM  
01:50PM  
09:50AM  
May-01-20 02:15PM  
01:05PM  
09:56AM  
Apr-30-20 06:23PM  
06:05PM  
Apr-29-20 08:00PM  
06:30PM  
03:01PM  
11:00AM  
09:45AM  
Apr-28-20 09:30PM  
04:34PM  
Apr-27-20 06:35PM  
12:45PM  
Apr-26-20 01:34AM  
Apr-25-20 09:29AM  
Apr-23-20 05:25PM  
03:30PM  
Apr-22-20 07:28PM  
04:28PM  
10:20AM  
Apr-21-20 08:01AM  
Apr-20-20 12:15PM  
Apr-18-20 06:08PM  
Apr-17-20 05:45PM  
Apr-16-20 08:03AM  
Apr-15-20 07:30PM  
02:30PM  
Apr-14-20 02:30PM  
Apr-13-20 09:00AM  
Allakos Inc. operates as a clinical stage biopharmaceutical company. The company is developing antolimab (AK002) for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RASMUSSEN HENRIK S MDChief Medical OfficerMar 03Option Exercise1.1620,00023,250123,771Mar 03 09:55 PM
Tomasi AdamPresident, COO and CFOMar 03Sale113.563,189362,143153,126Mar 03 09:59 PM
RASMUSSEN HENRIK S MDChief Medical OfficerMar 03Sale112.9821,9522,480,244101,819Mar 03 09:55 PM
RASMUSSEN HENRIK S MDChief Medical OfficerMar 02Option Exercise1.1620,00023,250125,087Mar 03 09:55 PM
RASMUSSEN HENRIK S MDChief Medical OfficerMar 02Sale117.3220,0002,346,400105,087Mar 03 09:55 PM
RASMUSSEN HENRIK S MDChief Medical OfficerMar 01Option Exercise1.1620,00023,250125,087Mar 03 09:55 PM
RASMUSSEN HENRIK S MDChief Medical OfficerMar 01Sale120.6620,0002,413,200105,087Mar 03 09:55 PM
Walker Paul EdwardDirectorDec 31Sale140.4635,0234,919,3782,163,260Jan 04 05:51 PM
Walker Paul EdwardDirectorDec 30Sale141.7168,3929,691,8532,198,283Jan 04 05:51 PM
Tomasi AdamPresident, COO and CFODec 29Option Exercise4.315,41623,356157,757Dec 31 09:04 PM
Alexander RobertChief Executive OfficerDec 29Option Exercise4.318,24035,535241,105Dec 31 09:03 PM
NOHRA GUY P10% OwnerJun 17Sale75.627,692581,6930Jun 19 07:24 PM
MORE ROBERT Jmember - potential 10% groupMay 18Sale71.5811,538825,9390May 20 06:08 PM
Hudson Peter Amember - potential 10% groupMay 18Sale71.8611,538829,0850May 20 06:07 PM
MCKEARN JOHN PDirectorMay 12Sale71.041,150,00081,696,0005,750,506May 14 06:28 PM
RiverVest Venture Fund III, L.10% OwnerMay 12Sale71.041,150,00081,696,0005,750,506May 14 06:25 PM